Nuclear excision repair-based personalized therapy for non-small cell lung cancer: From hypothesis to reality

International Journal of Biochemistry and Cell Biology

Volumn 39, Issue 7-8, 2007, Pages 1318-1328

  Simon, George R ^a   Ismail Khan, Roohi ^a   Bepler, Gerold ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Adjuvant and metastatic; Chemotherapy; Cisplatin; ERCC1; Lung cancer; Nuclear excision repair

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; NAVELBINE; PACLITAXEL;

ADVANCED CANCER; CANCER PATIENT; CANCER STAGING; CARCINOGENESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; EARLY CANCER; EXCISION REPAIR; GENETIC POLYMORPHISM; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; PREDICTOR VARIABLE; PROGNOSIS; PROTEIN EXPRESSION; SHORT SURVEY; TREATMENT RESPONSE;

CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE II; DNA DAMAGE; DNA REPAIR; DNA-BINDING PROTEINS; ENDONUCLEASES; HUMANS; LUNG NEOPLASMS; POLYMORPHISM, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 34447109660     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2007.05.006     Document Type: Short Survey

References (39)

1. Arriagada R., Bergman B., Dunant A., Le Chevalier T., Pignon J.P., and Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N. Engl. J. Med. 350 4 (2004) 351-360
2. Bepler G., Gautam A., McIntyre L.M., Beck A.F., Chervinsky D.S., Kim Y.C., Pitterle D.M., et al. Prognostic significance of molecular genetic aberrations on chromosome segment 11p15.5 in non-small cell lung cancer. J. Clin. Oncol. 20 5 (2002) 1353-1360
3. Bepler G., Kusmartseva I., Sharma S., Gautam A., Cantor A., Sharma A., et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J. Clin. Oncol. 24 29 (2006) 4731-4737
4. Bepler G., Sharma S., Cantor A., Gautam A., Haura E., Simon G., et al. RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J. Clin. Oncol. 22 10 (2004) 1878-1885
5. Bewick M.A., Conlon M.S., and Lafrenie R.M. Polymorphisms in XRCC1, XRCC3, and CCND1 and survival after treatment for metastatic breast cancer. J. Clin. Oncol. 24 36 (2006) 5645-5651
6. Ceppi P., Volante M., Novello S., Rapa I., Danenberg K., Danenberg P., et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann. Oncol. 17 12 (2006) 1818-1825
7. Cheng L., Spitz M.R., Hong W.K., and Wei Q. Reduced expression levels of nucleotide excision repair genes in lung cancer: A case-control analysis. Carcinogenesis 21 8 (2000) 1527-1530
8. Chiappori A., Simon G., Rocha Lima C., Williams C., Haura E., Vaughn J., et al. Phase II study of sequential gemcitabine(G) and carboplatin(C) followed by docetaxel(D) as first-line chemotherapy for patients with advanced non-small cell lung cancer. Lung Cancer 41 2 (2003) S225
9. Dabholkar M., Bostick-Bruton F., Weber C., Bohr V.A., Egwuagu C., and Reed E. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J. Natl. Cancer Inst. 84 19 (1992) 1512-1517
10. de Laat W.L., Jaspers N.G., and Hoeijmakers J.H. Molecular mechanism of nucleotide excision repair. Genes Dev. 13 7 (1999) 768-785
11. Edelman M.J. Gemcitabine and carboplatin regimens in advanced non-small-cell lung cancer: Focus on randomized phase III trials. Clin. Lung Cancer 4 Suppl. 2 (2003) S40-S44
12. Fossella F.V., DeVore R., Kerr R.N., Crawford J., Natale R.R., Dunphy F., et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J. Clin. Oncol. 18 12 (2000) 2354-2362
13. Fossella F., Pereira J.R., von Pawel J., Pluzanska A., Gorbounova V., Kaukel E., et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group. J. Clin. Oncol. 21 16 (2003) 3016-3024
14. Gridelli C., Frontini L., Perrone F., Gallo C., Gulisano M., Cigolari S., et al. Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses. Gem Vin Investigators. Br. J. Cancer 83 6 (2000) 707-714
15. Hanna N., Bunn Jr. P.A., Langer C., Einhorn L., Guthrie Jr. T., Beck T., et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J. Clin. Oncol. 24 13 (2006) 2038-2043
16. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 22 9 (2004) 1589-1597
17. Hoeijmakers J.H. Nucleotide excision repair. I. From E. coli to yeast. Trends Genet. 9 5 (1993) 173-177
18. Hoeijmakers J.H. Nucleotide excision repair. II. From yeast to mammals. Trends Genet. 9 6 (1993) 211-217
19. Houtsmuller A.B., Rademakers S., Nigg A.L., Hoogstraten D., Hoeijmakers J.H., and Vermeulen W. Action of DNA repair endonuclease ERCC1/XPF in living cells. Science 284 5416 (1999) 958-961
20. Kelly K., Crowley J., Bunn Jr. P.A., Presant C.A., Grevstad P.K., Moinpour C.M., et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial. J. Clin. Oncol. 19 13 (2001) 3210-3218
21. Kosmidis P., Mylonakis N., Nicolaides C., Kalophonos C., Samantas E., Boukovinas J., et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: A phase III randomized trial. J. Clin. Oncol. 20 17 (2002) 3578-3585
22. Le Chevalier, T. (2003). Results of the Randomized Adjuvant Lung Cancer Trial (IALT): Cisplatin-based chemotherapy (CT) vs. no CT in 1867 Patients with resected non-small cell lung cancer (NSCLC). Proc ASCO, 21.
23. Le Chevalier T., Scagliotti G., Natale R., Danson S., Rosell R., Stahel R., et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 47 1 (2005) 69-80
24. Lord R.V., Brabender J., Gandara D., Alberola V., Camps C., Domine M., et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin. Cancer Res. 8 7 (2002) 2286-2291
25. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350 21 (2004) 2129-2139
26. McCabe A., Dolled-Filhart M., Camp R.L., and Rimm D.L. Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J. Natl. Cancer Inst. 97 24 (2005) 1808-1815
27. Metzger R., Leichman C.G., Danenberg K.D., Danenberg P.V., Lenz H.J., Hayashi K., et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J. Clin. Oncol. 16 1 (1998) 309-316
28. Olaussen K.A., Dunant A., Fouret P., Brambilla E., Andre F., Haddad V., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 355 10 (2006) 983-991
29. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304 5676 (2004) 1497-1500
30. Rosell, R., Cobo, M., Isla, D., Massuti, B., Montes, A., Paz-Ares, M., et al. (2005). ERCC1 mRNA-based randomized Phase III trial of docetaxel (doc) doublets with cisplatin (cis) or gemcitabine (gem)in stage IV non-small clell lung cancer (NSCLC) patients (p). Proc ASCO, 23, 621s.
31. Rosell R., Gatzemeier U., Betticher D.C., Keppler U., Macha H.N., Pirker R., et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: A cooperative multinational trial. Ann. Oncol. 13 10 (2002) 1539-1549
32. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 346 2 (2002) 92-98
33. Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 18 10 (2000) 2095-2103
34. Shirota Y., Stoehlmacher J., Brabender J., Xiong Y.P., Uetake H., Danenberg K.D., et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J. Clin. Oncol. 19 23 (2001) 4298-4304
35. Simon G.R., Sharma S., Cantor A., Smith P., and Bepler G. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 127 3 (2005) 978-983
36. Simon, G. R., Sharma, A., Li, X., Hazelton, T., Walsh, F., Williams, C., et al. (2007). Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 25, in press.
37. Smit E.F., van Meerbeeck J.P., Lianes P., Debruyne C., Legrand C., Schramel F., et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: A phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J. Clin. Oncol. 21 21 (2003) 3909-3917
38. Stubbe J. Ribonucleotide reductases in the twenty-first century. Proc. Natl. Acad. Sci. U.S.A. 95 6 (1998) 2723-2724
39. Warnecke-Eberz U., Metzger R., Miyazono F., Baldus S.E., Neiss S., Brabender J., et al. High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Clin. Cancer Res. 10 11 (2004) 3794-3799